Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05212922
Other study ID # YH001004
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date June 2023
Est. completion date March 2025

Study information

Verified date November 2022
Source Eucure (Beijing) Biopharma Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab,The study is designed to determine the safety ,tolerability and antitumor activity of YH001 in combination with Toripalimab in subjects with advanced NSCLC and HCC.


Description:

This study will include two cohorts of up to 40 subjects each treated with RP2D dose YH001 in combination with 240 mg Toripalimab to assess the antitumor activity and safety/tolerability. According to Simon's two stage design, in the first stage, 9-10 subjects will be accrued. If there are ≤ 1 subjects achieving an objective response, the futility stop will be called. Enrollment will start for the second stage after Stage 1 data pass futility test. In the second stage, 17-19 subjects will be enrolled to have 27 subjects in total. If there are ≥ 5 subjects achieving an objective response, a stop could be called for meeting the primary objective. In all cohorts, 4 mg/kg or other higher dose level of YH001 (not exceeding MTD) may be needed based on the safety data in the first stage. - Cohort A: YH001 in combination with Toripalimab in subjects with advanced PD-L1 positive NSCLC as 1st line treatment; - Cohort B: YH001 in combination with Toripalimab in subjects with previously systemically treated advanced HCC as 2nd line treatment;


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female, aged = 18 years; 2. Willing and able to provide signed and dated informed consent prior to any study-related procedures and willing and able to comply with all study procedures. 3. Target Population Cohort A: - Have histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) - Recurrent or unresectable locally advanced (Stage IIIB) or metastatic (Stage IV); - Naïve to any systemic anti-cancer therapy - No EGFR mutation or ALK/ ROS1 gene rearrangement - PD-L1 positive (TPS=1%) NSCLC Cohort B: - HCC diagnosis confirmed by or radiology, histology, or cytology; - Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy and not amenable to a curative treatment approach; - Child-Pugh A liver score within 7 days prior to first dose of study drug; - Documented objective radiographic progression during or after treatment with sorafenib/lenvatinib, or intolerant of sorafenib/lenvatinib; or documented objective radiographic progression during or after treatment with atezolizumab and bevacizumab, or intolerant of atezolizumab and bevacizumab. 4. At least 1 unidimensional measurable target lesion per RECIST v1.1 5. ECOG performance status score 0 or 1 6. Have life expectancy of at least 12 weeks based on investigator's judgement. 7. Adequate organ and bone marrow function: 8. Women of reproductive potential must have negative serum beta human chorionic gonadotropin (ß -HCG) pregnancy test within 7 days of the fist dose of YH001. 9. Women of reproductive potential who are sexually active with a non-sterilized male must consistently use highly effective contraception/birth control between signing of the informed consent and 120 days after the last administration of the study drug. Exclusion Criteria: 1. Treatment with any investigational drug within 4 weeks prior to the fist dose of study drug; 2. Prior anticancer therapy: - Cohort B: Subjects received sorafenib/lenvatinib within 14 days of first dose of study medication. - Prior palliative radiotherapy to bone metastases = 2 weeks prior to the first dose of YH001 is acceptable. - It is unacceptable to have wash out less than 2 weeks for herbal therapy approved for anticancer. 3. Subjects with prior anti-CTLA-4 checkpoint inhibitors should be excluded. 4. Subjects with a history of = Grade 3 immune-related adverse events resulted from previous immunotherapy or an AE of any grade that resulted in discontinuation of prior immunotherapy 5. History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis, or history of interstitial lung disease 6. Subjects requiring systemic treatment with corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive medications within 21 days before the planned first dose of study drug or has need to be treated while on trial 7. Allergic to YH001 and Toripalimab or any component of the study drug formulation. 8. Subjects with concomitant active autoimmune disease, history of autoimmune disease requiring systemic treatment, or history of autoimmune disease within the two years prior to study entry. 9. Primary central nervous system (CNS) malignancies or symptomatic CNS metastases. 10. Subjects with severe cardiovascular diseases, e.g. New York Heart Association (NYHA) Class III or IV heart failure, myocardial infection within 6 months prior to first dose of YH001, uncontrolled hypertension, unstable angina pectoris or unstable cardiac arrhythmia. 11. QTcF > 470 ms at baseline; no concomitant medications that would prolong the QT interval; no family history of long QT syndrome. 12. Viral infection: - Acute or Chronic active Hepatitis B (HBsAg positive and HBV DNA=2000 IU/mL). - Chronic HCV infection (HCV antibody positive and HCV RNA detectable). - Human immunodeficiency virus (HIV) infection as well as COVID-19. 13. Subjects with active tuberculosis are excluded. Subjects who have received BCG vaccination may have a false positive PPD test. These subjects are eligible if they have a negative Interferon Gamma Release Assay (IGRA). 14. Clinically uncontrolled concurrent illnesses, including, but not limited to, active infection that requires systematic treatment, serious diabetes (fasting blood glucose > 250 mg/dl), psychiatric illness that would limit compliance with the study requirements and other serious medical illnesses requiring systemic therapies. 15. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that have not recovered to = Grade 1 per CTCAE v5.0 16. Failure to recover adequately, as judged by the investigator, from prior surgical procedures; the subjects have had major surgery within 28 days, or minor surgery within 2 weeks prior to the first dose of YH001. 17. Subjects received any live or attenuated vaccine within 28 days prior to the first dosing of study drug. For inactivated or attenuated COVID -19 vaccine, follow local guidelines. 18. Pregnant or breast-feeding females. 19. Any clinically significant abnormality in the laboratory 20. Subjects have another active invasive malignancy within 5 years 21. Cohort B: - History of esophageal or gastric variceal bleeding within the last 6 months, or current active gastrointestinal bleeding; - Large tumor lesion in liver (=60% liver volum), portal vein invasion at the main portal branch (Vp4), inferior vena cava, or cardiac involvement of HCC based on imaging; - Clinically diagnosed hepatic encephalopathy in the last 6 months

Study Design


Intervention

Drug:
YH001 + Toripalimab
YH001 + Toripalimab

Locations

Country Name City State
Armenia Gabrail Cancer Center Research Canton Ohio
Australia Andrew Love Cancer Centre Geelong Victoria
Australia University of New South Wales (UNSW) - Liverpool Hospital Liverpool New South Wales
Austria Coffs Harbour Health Campus Coffs Harbour New South Wales
China Beijing Cancer Hospital Beijing Beijing
China Beijing Tsinghua Changgung Hospital Beijing Beijing
China Bethune First Hospital Of Jilin University Changchun Jilin
China West China Hospital of Sichuan University Chengdu Sichuan
China Sir Run Run Shaw Hospital Zhejiang University School Of Medicine Hangzhou Zhejiang
China The Affiliated Tumour Hospital of Harbin Medical University Harbin Heilongjiang
China Nantong Tumor Hospital Nantong Jiangsu
China Shanghai Pulmonary Hospital Shanghai Shanghai
China Hubei Cancer Hospital Wuhan Hubei
China Zhongnan Hospital of Wuhan University Wuhan Hubei
China Henan Cancer Hospital Zhengzhou Henan
Taiwan Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital Kaohsiung
Taiwan Kaohsiung Medical University - Chung-Ho Memorial Hospital Kaohsiung
Taiwan China Medical University Hospital Taichung
Taiwan Chi Mei Medical Center - Liouying Tainan
Taiwan Chi Mei Medical Center - YongKang Tainan
Taiwan Taipei Medical University Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
Eucure (Beijing) Biopharma Co., Ltd

Countries where clinical trial is conducted

Armenia,  Australia,  Austria,  China,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Other trough concentration (Ctrough) To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other terminal half-life (T1/2). To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other Duration of response (DOR) To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1 maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other progression free survival (PFS) To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1 maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Other time to response (TTR) To assess other antitumor activity of YH001 in combination with Toripalimab by investigator's assessment according to the RECIST v1.1 maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Primary ORR Overall Response Rate (ORR) by investigator's assessment according to the RECIST v1.1 maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary safety and tolerability The safety and tolerability will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0 maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary OS To assess other antitumor activity of YH001 in combination with Toripalimab maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary anti-drug antibodies (ADA) Immunogenicity maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary neutralizing antibodies (NAbs). To assess the immunogenicity of YH001 in combination with Toripalimab maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
Secondary peak concentration (Cmax) To characterize the pharmacokinetic (PK) profiles of YH001 in combination with Toripalimab maximum of 1 years after the first dose of YH001 and Toripalimab study treatment.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05458115 - Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Enrolling by invitation NCT02256514 - Open Label Trial of Immunotherapy for Advanced Liver Cancer Phase 2
Completed NCT04542837 - The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma Phase 2
Not yet recruiting NCT05025592 - cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC
Completed NCT04172506 - A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06024252 - Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study
Not yet recruiting NCT05840133 - Study of Long Non-coding RNA SNHG15 as a Novel Biomarker in HBV Associated HCC
Terminated NCT02785874 - Statin With Palliative Therapy for HCC N/A
Not yet recruiting NCT02715492 - Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma. Phase 3
Completed NCT02985034 - Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT N/A
Not yet recruiting NCT06069947 - SALT for Liver Cirrhosis With HCC N/A
Recruiting NCT05581004 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Suspended NCT02935478 - Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation N/A
Recruiting NCT05592171 - Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC N/A
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05544253 - Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC Phase 2/Phase 3
Recruiting NCT06184152 - CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
Completed NCT02675920 - A Study of HCC High Risk Group Using Two Surveillance Tools
Completed NCT02833298 - Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening N/A